Text Size

Investigation Into the Correlation of Plasma Hs-CRP Concentrations and Cardiovascular Risk in Korean Population (CALLISTO)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00819273
First received: January 7, 2009
Last updated: December 2, 2010
Last verified: December 2010
History of Changes

January 7, 2009
December 2, 2010
March 2009
August 2009   (final data collection date for primary outcome measure)
Evaluate hs-CRP levels according to risk categories by the NCEP ATP III. [ Time Frame: Within the last 12 months from the date of data entry. ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00819273 on ClinicalTrials.gov Archive Site
Evaluate a relationship between hs-CRP and each CHD CVD risk factor including LDL-C. [ Time Frame: Within the last 12 months from the date of data entry. ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Investigation Into the Correlation of Plasma Hs-CRP Concentrations and Cardiovascular Risk in Korean Population
Investigation Into the CorrelAtion of pLasma Hs-CRP Concentrations and cardiovascuLar rISk in Korean populaTiOn

An observational, non-interventional, multi-centre study to provide further information on the utility of test for a predictive marker by investigating the current prevalence of high sensitivity CRP (hs-CRP) testing and characteristics of each CVD risk group.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample

Patients who have records of clinic visit with circulatory and endocrine internal medicines of nationwide tertiary hospitals within the last one year.
hsCRP
Not Provided
1
patients who have records of clinic visit with circulatory and endocrine internal medicines of nationwide tertiary hospitals within the last one year.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1700
August 2009
August 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects with at least one clinic visit record within the last 12 months from the date of data entry.
  • Subjects with at least one hs-CRP level measured within the last 12 months from the date of data entry.

Exclusion Criteria:

  • Use of statins or other lipid-lowering therapies including fibrates, niacin, and bile acid sequestrants in the past 3 months prior to hsCRP measurement
  • Active inflammatory diseases documented during the period of CRP measurement
  • Subjects taking immunosuppressants
  • Findings of chronic inflammation: arthritis, lupus, or inflammatory bowel disease
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Korea, Republic of
 
NCT00819273
NIS-CKR-DUM-2008/5
No
Hyunah Caroline, Choi / CV TA Physician, AstraZeneca Pharmaceuticals
AstraZeneca
Not Provided
Principal Investigator: Baek Sanghong, Ph.D. The Catholic University
AstraZeneca
December 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP